临床试验/IRCT20200105046010N6

IRCT20200105046010N6尚未招募未知

In- Vivo Bioequivalence study of Lenalidomide tablet 25mg ABIDI (MYLODEQ® 25mg) with brand drug (REVLIMID® 25mg Colgene, Bristol-Myers Squibb) in Iranian healthy volunteers.

Tabriz University of Medical Sciences0 个研究点目标入组 24 人开始时间: 待定最近更新: 2020年8月17日

适应症

试验速览

阶段: 未知
状态: 尚未招募
发起方: Tabriz University of Medical Sciences
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 years 至 60 years（—）
性别: All

入选标准

•General health(liver, heart, kidney)
•Body mass index(18-28)
•Informed consent
•Age(18-60)

排除标准

•A history of cardiovascular disease
•A history of liver & kidney disease
•Alcohol & Drug addiction
•Hypersensitivity to the drug

研究者

发起方

Tabriz University of Medical Sciences

相似试验

enalidomide cap. 25mg Sobhan Oncology (LENASOB® 25mg), In-Vivo Bioequivalence in iranian healthy volunteer.In this study, the disease is not examined. Subject bioequivalence test and reference tablets Teriflunomide studied..

IRCT20200105046010N26SOBHAN ONCOLOGY Pharmaceutical24

In-vivo Bioequivalence Test of Linalidomide capsules with brand drug (REVLIMID® 25 mg, Celgene, Bristol-Myers Squibb, UK)

IRCT20200105046010N53Actero middle east Pharm. Co.24

In-vivo Bioequivalence study of Tadalafil tablet with brand drugs (CIALIS Lilly USA)

IRCT20200105046010N39Mofid Pharmaceutical Co.24

evetiracetam tablet 1000mg (LEVEBEL 1000mg, Cobel Darou) In- Vivo Bioequivalence study in Iranian healthy volunteersin this study the bioequivalence of test and brand of levetiracetam will evaluated..

IRCT20200105046010N1Cobel Darou Pharmaceutical Company24

igagliptin tablets 5mg ABIDI Pharmaceuticals (TRAJENTA® 5mg Tab) , In- Vivo Bioequivalence in Iranian healthy volunteers.

IRCT20200105046010N8Tabriz University of Medical Sciences24